We’re excited to attend BioChallenge 2026 on October 29 at the New Orleans BioInnovation Center! BioChallenge brings neuro-focused startups to the stage, connecting emerging companies with the funding, resources, expertise, and partnerships needed to accelerate innovation and growth. Meet with Sami Shihabi to learn more about how Circular Genomics is advancing blood-based circular RNA biomarkers to support earlier detection and prediction of Alzheimer’s disease progression. Schedule a meeting by filling out this form: na2.hubs.ly/H08FmN90 We look forward to connecting with fellow innovators, investors, and leaders working to advance neuroscience and improve brain health. #BioChallenge2026 #CircularGenomics #Neuroscience #AlzheimersResearch #Biotechnology

Mental health is an essential part of living a healthy, fulfilling life. When we prioritize mental well-being, we create healthier individuals, stronger relationships, and more resilient communities. Today, we’re taking a moment to reflect on the importance of mental health and the role each of us can play in supporting it. Behind every statistic is a person, a family, and a story. Taking care of our mental health shouldn’t be an afterthought — it should be part of how we care for our overall health. At Circular Genomics, we believe that advancing our understanding of brain health can help contribute to a future where neurological health is better understood, detected earlier, and more thoughtfully supported. This World Mental Health Day, let’s continue to break the stigma, make space for honest conversations, and remind one another that mental health matters. #WorldMentalHealthDay #BrainHealth

Circular Genomics and Altoida today announced a collaboration combining Circular Genomics’ blood-based circular RNA (circRNA) biomarker platform with Altoida’s AI-powered Digital NeuroMarker™ platform. The alliance is designed to advance an integrated biology-and-function approach to Alzheimer’s drug development and frontline healthcare, creating a first-of-kind multimodal approach to: - Improve early identification of Alzheimer’s disease - Enable more precise patient stratification - Support longitudinal monitoring of disease progression By combining biological insights from blood-based circRNA biomarkers with AI-powered digital measures of cognitive and functional performance, the collaboration aims to provide a more comprehensive view of the individual and their disease trajectory. Read the full press release to learn more: na2.hubs.ly/H07YRc00 #AlzheimersDisease #PrecisionMedicine #Biomarkers #DigitalHealth #CircularRNA #AI #Neuroscience #AlzheimersResearch #DrugDevelopment

Behind every Alzheimer’s statistic is a person. A parent. A partner. A friend. A family navigating uncertainty, difficult decisions, and the gradual changes that can reshape a life. On World Alzheimer’s Day, we honor everyone affected by Alzheimer’s disease and the families, caregivers, clinicians, and researchers working toward a different future. At Circular Genomics, we believe that future starts with understanding Alzheimer’s disease earlier. Our mission is to help make Alzheimer’s disease more detectable, more understandable, and ultimately more manageable—so that more people can have more time, more answers, and more hope. #WorldAlzheimersDay #AlzheimersDisease #AlzheimersResearch #Biomarkers #BrainHealth #Neuroscience #EarlyDetection

Alzheimer's disease biology & pathology begin years before symptoms appear, making early detection essential for timely intervention and access to emerging disease-modifying therapies. In this featured article, we explore how blood-based circular RNA (circRNA) biomarkers are reshaping Alzheimer's diagnostics—offering a minimally invasive approach that can detect disease pathology, predict progression, and capture multiple biological pathways in a single blood test. Recent findings published in Nature Medicine demonstrate that a 34-circRNA signature achieved strong diagnostic performance and predicted progression to symptomatic Alzheimer's disease across independent cohorts. Read the latest feature on how blood-based circular RNA is advancing the early detection of Alzheimer's disease: na2.hubs.ly/H072XNW0 #AlzheimersDisease #CircularRNA #Biomarkers #PrecisionMedicine #Neuroscience #Diagnostics #Biotechnology

We're excited to share that our abstract, "Blood-Based Circular RNA Signatures Predict Presymptomatic Alzheimer's Disease Progression Across Independent Cohorts," has been accepted for presentation at the USC Alzheimer's Research Day Symposium in San Diego on Wednesday, August 5, 2026. We're also honored that our co-founder and Chief Scientific Officer, Nikolaos Mellios, has been invited to deliver an oral presentation at the symposium, highlighting our latest research on blood-based circular RNA biomarkers for predicting Alzheimer's disease progression before symptoms emerge. This recognition underscores the growing potential of circular RNA to enable earlier detection of Alzheimer's disease and advance more accessible, precision-based diagnostics. If you'll be attending the symposium, we'd love to connect and discuss how circular RNA is shaping the future of neurodegenerative disease research. #AlzheimersDisease #Neuroscience #Biomarkers #CircularRNA #PrecisionMedicine #Research #USC #Neurodegeneration

The search for earlier, more accessible Alzheimer's disease biomarkers is accelerating and circular RNA is emerging as a promising new frontier. Join Circular Genomics for an exclusive webinar featuring Nikolas Mellios, MD, PhD and Henrik Zetterberg, MD, PhD, two leaders in neuroscience and biomarker research, as they examine the growing role of brain-derived circular RNA (circRNA) in advancing Alzheimer's disease detection. During this discussion, they'll cover: 🧬 What makes circRNA a uniquely stable and biologically meaningful biomarker 🩸 How brain-derived circRNA can be measured through a simple blood sample 📈 New clinical evidence supporting its ability to identify Alzheimer's disease and predict disease progression 🚀 Where circRNA research is headed and its potential impact on future diagnostic strategies Reserve your spot today: na2.hubs.ly/H06Mxyq0 #AlzheimersDisease #circRNA #Biomarkers #Neurodegeneration #PrecisionMedicine #Neuroscience #Biotech

Our new website is live! We're excited to unveil the newly redesigned Circular Genomics website—a refreshed digital experience that makes it easier to explore our science, technology, and mission to transform brain health through circular RNA. Whether you're a researcher, clinician, industry partner, or investor, our new website offers a streamlined experience to help you learn how Circular Genomics is advancing the future of precision diagnostics and brain health. 🌐 Visit us today: na2.hubs.ly/H06MxtV0 #CircularGenomics #CircularRNA #BrainHealth #PrecisionMedicine #Biotechnology #AlzheimersDisease #Diagnostics #Innovation

Thank you to everyone who connected with us at the Alzheimer's Association International Conference (AAIC) 2026 in London! It was a pleasure meeting with researchers, clinicians, collaborators, and industry leaders from around the world to discuss the future of Alzheimer's disease diagnostics and the potential of circular RNA. We appreciated the opportunity to share how CircPATH™ leverages the unique biology of circular RNA to deliver pathway-level insights into neurodegenerative disease, advancing the next generation of precision diagnostics. See you at the next conference! #AAIC2026 #CircularGenomics #CircPATH #CircularRNA #AlzheimersDisease #BrainHealth #PrecisionMedicine #Biotechnology

We're heading to London for #AAIC2026! The Circular Genomics team is excited to attend the Alzheimer's Association International Conference (AAIC) 2026, where the global Alzheimer's and dementia research community comes together to share the latest scientific advances in prevention, diagnosis, treatment, and care. We're looking forward to connecting with researchers, clinicians, industry partners, and collaborators to discuss how our CircPATH™ platform is advancing the next generation of precision diagnostics for Alzheimer's disease. If you'll be attending AAIC, we'd love to meet with you. Connect with our team to learn more about our science, technology, and vision for transforming neurodegenerative disease diagnostics. Contact us at [email protected] to schedule a meeting. 📅 See you in London! #AAIC2026 #Alzheimers #DementiaResearch #PrecisionMedicine #Biotechnology #CircularRNA #Diagnostics #Neuroscience #LifeSciences

We are proud to announce the launch of CircPath™, our proprietary circular RNA (circRNA) platform, following a landmark study published in Nature Medicine demonstrating breakthrough performance in the early detection of Alzheimer’s disease. CircPath™ leverages the unique biology of circular RNAs to provide pathway-level insights into neurodegenerative disease, advancing a new generation of precision diagnostics designed to improve how Alzheimer's disease is detected, monitored, and managed. We are grateful for the support of the Alzheimer's Drug Discovery Foundation and all of our collaborators as we continue our mission to bring more accessible, biology-driven tools to patients, clinicians, and researchers. Read the full press release and learn more about CircPath™: na2.hubs.ly/H06s4Qs0 Read the publication: na2.hubs.ly/H06s4lM0

BIO 2026 is coming to San Diego—right in our backyard—and we're excited to be part of it! Join our Chief Commercial Officer, Sami Shihabi and our Sr. Director of Business Development, Justin T. Brown, June 22–25 to learn how Circular Genomics is advancing precision medicine through innovative circular RNA (circRNA) blood-based biomarker tests designed to unlock deeper insights into disease biology. 📍 San Diego Convention Center | June 22–25, 2026 Interested in connecting? Fill out the form below to schedule time with our team or request a meeting through the BIO Partnering platform: Interested in connecting? Fill out the form below to schedule time with our team or request a meeting through the BIO Partnering platform: na2.hubs.ly/H065_LC0 #BIO2026 #CircularRNA #PrecisionNeurology #BloodBasedBiomarkers #Diagnostics

June is Alzheimer’s & Brain Awareness Month 💜 More than 55 million people worldwide are living with dementia, with Alzheimer's disease accounting for the majority of cases. This month, we join patients, caregivers, clinicians, researchers, and advocates in raising awareness of the urgent need for earlier detection, better treatment options, and continued innovation in brain health. At Circular Genomics, we are committed to advancing precision neurology through the development of novel circular RNA (circRNA)-based blood biomarkers designed to provide deeper insight into the biology of neurodegenerative disease and support the future of personalized care. Together, we can help accelerate research, increase awareness, and work toward a future where neurodegenerative diseases are detected earlier and managed more effectively. #AlzheimersAwarenessMonth #BrainAwarenessMonth #AlzheimersDisease #DementiaAwareness #PrecisionMedicine #Neurology #Biomarkers #Neurodegeneration #BrainHealth #CircularGenomics #CircRNA #HealthcareInnovation

We’re excited to announce a strategic alliance with Vitazi.ai, an innovator in AI-powered retinal imaging and oculomics, to co-develop a next-generation, multimodal workflow for the early detection and risk stratification of Alzheimer’s disease. This collaboration brings together complementary technologies to create a first-in-class diagnostic approach, addressing critical gaps in early-stage patient identification while expanding the reach and impact of both platforms. Read the full press release to learn more: na2.hubs.ly/H05b9wx0

Early detection changes everything. In the fight against Alzheimer’s, time is our most valuable resource. New research into circular RNAs (circRNAs) is turning the dream of a simple, reliable blood test into a reality. Because of their unique stability and brain enrichment, circRNAs are helping us detect disease markers sooner than ever before and can enable: - Improved care pathways - More informed family decisions - Better long-term patient outcomes Learn how we’re scaling the future of diagnostics in our new whitepaper: na2.hubs.ly/H056GQY0

We’re pleased to welcome Henrik Zetterberg, MD, PhD to our Scientific Advisory Board. A Professor of Neurochemistry at the University of Gothenburg, University of Wisconsin–Madison, and UCL, Dr. Zetterberg is a global leader in fluid biomarkers for neurodegenerative diseases. His expertise will further advance Circular Genomics’ mission to make brain disorders measurable through innovative circRNA biomarker technology, including blood-based assays for Alzheimer’s diagnosis and risk prediction. Read the press release to learn more: na2.hubs.ly/H053MJz0

Did you know that 75% of dementia cases worldwide go undiagnosed? 🌍 For too long, getting an answer has meant jumping through hoops. Traditional diagnostics rely on a complex ""triple threat"" of testing: Cognitive Testing: Stressful exams that often catch the disease too late. Lumbar Punctures: Invasive and intimidating procedures. High-Tech Imaging: Expensive PET or MRI scans with limited availability. While these tools are effective, they aren't scalable—resulting in millions of people being left in the dark during the most critical window for treatment. At Circular Genomics, our research and technology using Circular RNA (circRNA) aims to provide insight into the underlying biology of Alzheimer's Disease, offering a clearer path toward early detection and personalized care. Learn more: na2.hubs.ly/H04tLwt0"

Alzheimer’s is the 6th leading cause of death in the U.S., and someone develops it every ~65 seconds. Early detection is critical. Identifying cognitive changes sooner gives patients the opportunity to take proactive steps to manage risk and plan for the future. At Circular Genomics, we’re developing non-invasive blood-based tests to detect Alzheimer’s earlier, helping empower patients and clinicians with actionable insights when it matters most. Learn more: na2.hubs.ly/H049Q8b0 #AlzheimersAwareness #EarlyDetection #BrainHealth #CognitiveWellness #CircularGenomics #BloodBiomarker

Studies show that lifestyle changes—regular exercise, a balanced diet, mental stimulation, and routine health check-ups—can improve cognition in older adults at risk of cognitive decline. The U.S. POINTER trial, the first large-scale RCT in the U.S., demonstrates that accessible, multidomain lifestyle interventions can protect cognitive function across diverse populations. 🔑 Why it matters: Early detection helps identify who is at risk, giving patients and caregivers the chance to take proactive steps to slow or delay cognitive decline. Everyday lifestyle choices can truly make a difference. Learn more about the study: na2.hubs.ly/H049K7S0 #BrainHealth #EarlyDetection #CognitiveWellness #AlzheimersPrevention #HealthyAging #USPOINTER

On #EmployeeAppreciationDay, we recognize the remarkable team behind Circular Genomics. Your dedication to advancing care for patients with psychiatric and neurological disorders is what drives our mission forward. Thank you for your passion, innovation, and relentless commitment to making a difference for patients and their families. #CircularGenomics #Teamwork #Innovation